Ftse Mib
38.327,72
0,92%
DAX
22.798,09
1,40%
S&P 500
6.114,63
-0,01%
NASDAQ
20.026,77
0,41%
Bitcoin
96.231,50
0,48%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ UroGen Pharma Ltd (URGN) UroGen Pharma Ltd (URGN) Notizie

URGN

UroGen Pharma (URGN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:URGN
DataOraFonteTitoloSimboloCompagnia
14/02/202520:30Business WireUroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102NASDAQ:URGNUroGen Pharma Ltd
12/02/202514:00Business WireData from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of UrologyNASDAQ:URGNUroGen Pharma Ltd
04/02/202517:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
30/01/202514:00Business WireUroGen Pharma to Present at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
22/01/202514:00Business WireNew Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)NASDAQ:URGNUroGen Pharma Ltd
15/01/202514:00Business WireENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025NASDAQ:URGNUroGen Pharma Ltd
14/01/202513:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
06/12/202414:00Business WireUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:URGNUroGen Pharma Ltd
05/12/202421:30Business WireLong-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®NASDAQ:URGNUroGen Pharma Ltd
05/12/202421:15Business WireUGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBCNASDAQ:URGNUroGen Pharma Ltd
02/12/202414:00Business WireUroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet NeedsNASDAQ:URGNUroGen Pharma Ltd
26/11/202414:00Business WireNew Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®NASDAQ:URGNUroGen Pharma Ltd
18/11/202412:16Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:URGNUroGen Pharma Ltd
06/11/202414:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:URGNUroGen Pharma Ltd
06/11/202414:00Business WireUroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025NASDAQ:URGNUroGen Pharma Ltd
05/11/202414:00Business WireUroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation ConferenceNASDAQ:URGNUroGen Pharma Ltd
30/10/202413:00Business WireUroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024NASDAQ:URGNUroGen Pharma Ltd
28/10/202413:00Business WireENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBCNASDAQ:URGNUroGen Pharma Ltd
15/10/202422:30Business WireUroGen Announces FDA Acceptance of its New Drug Application for UGN-102NASDAQ:URGNUroGen Pharma Ltd
09/10/202422:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
09/10/202414:00Business WireUroGen Appoints Chris Degnan as Chief Financial OfficerNASDAQ:URGNUroGen Pharma Ltd
02/10/202414:00Business WireFirst Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNASDAQ:URGNUroGen Pharma Ltd
16/09/202414:00Business WireUroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041NASDAQ:URGNUroGen Pharma Ltd
10/09/202413:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:URGNUroGen Pharma Ltd
14/08/202414:00Business WireUroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNASDAQ:URGNUroGen Pharma Ltd
13/08/202414:00Business WireUroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business HighlightsNASDAQ:URGNUroGen Pharma Ltd
05/08/202414:00Business WireUroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024NASDAQ:URGNUroGen Pharma Ltd
09/07/202423:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:URGNUroGen Pharma Ltd
18/06/202423:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:URGNUroGen Pharma Ltd
18/06/202404:51Business WireUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:URGNUroGen Pharma Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:URGN

La tua Cronologia

BIT
S18357
Societe Generale Iss
USOTC
COSAF
Cosa Resources (QB)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci